Bora to Expand Rare Disease Portfolio with Acquisition of Pyros
26 Oct 2024 //
PRESS RELEASE
Pyros Pharmaceuticals Launches VIGAFYDE, Ready-to-Use Vigabatrin Solution
03 Sep 2024 //
BUSINESSWIRE
Pyros Pharma Abstract Accepted For Poster At AES 2024 Annual Meeting
20 Aug 2024 //
BUSINESSWIRE
Pyros Pharma`s Vigafyde (vigabatrin) Receives Approval in the U.S
20 Jun 2024 //
FDA
Pyros Pharmaceuticals Announces FDA Approval of VIGAFYDE™
18 Jun 2024 //
BIOSPACE
Pyros Pharms New Vigabatrin Receives Approval in US
17 Jun 2024 //
FDA
Pyros Pharma Announces FDA Approval Of VIGAFYDE™ Oral Solution
17 Jun 2024 //
BUSINESSWIRE
Pyros Pharmaceuticals Announces VIGPODER™ (vigabatrin) is Now Available
01 Apr 2024 //
BUSINESSWIRE
Pyros Announces Positive Outcome of the Procedure for Approval of VIGZIP
15 Feb 2024 //
BUSINESSWIRE
Pyros Pharmaceuticals’ Abstract Accepted for Poster Presentation
10 Oct 2023 //
BUSINESSWIRE